Close Menu

NEW YORK (GenomeWeb) – The European Commission has approved AstraZeneca and Merck's olaparib (Lynparza) as a maintenance treatment for patients with ovarian, fallopian tube or primary peritoneal cancer if they've responded to first-line, platinum-based chemotherapy and have germline or somatic BRCA1/2 mutations. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.